Xolair, Omalizumab is a monoclonal antibody targeting the high-affinity receptor binding site on human immunoglobulin E (IgE). Currently, omalizumab has been approved for the treatment of persistent allergic asthma in patients who are poorly controlled with inhaled corticosteroids. However, other allergic disorders may be amenable to treatment with omalizumab because of its ability to inhibit effector functions of IgE. Treatment with omalizumab should be administered by specialists with training in diagnosis and treatment of allergic asthma. The treatment should be withheld if no positive treatment effects are observed after 4 months.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Maternal smoking during infancy increases the risk of allergic diseases in children: a nationwide longitudinal survey in Japan.
Allergy Asthma Clin Immunol
January 2025
Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Background: The incidence of allergic diseases has been increasing in Japan. In particular, a serious decline in the age of onset of allergic rhinitis has been observed. Passive smoking from parental smoking has a significant impact on children's health; however, it is difficult to restrict smoking in the home.
View Article and Find Full Text PDFThe effect of allergic rhinitis treatment on asthma control: a systematic review.
NPJ Prim Care Respir Med
January 2025
Erasmus MC, Department of General Practice, Rotterdam, The Netherlands.
Asthma and allergic rhinitis (AR) are common disorders of the respiratory tract that often coincide. Control of AR symptoms can improve asthma outcomes in patients with co-existing diseases. Our aim is to produce a systematic review of the effectiveness of conventional anti-AR medication for asthma outcomes in patients with both diseases.
View Article and Find Full Text PDFMetabolomic profiles in allergic rhinitis: a systematic review and meta-analysis.
Ann Allergy Asthma Immunol
January 2025
The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; Lingnan Institute of Otolaryngology, Guangdong Clinical Research Academy of Chinese Medicine, Guangzhou, 510405, China. Electronic address:
Background: Allergic rhinitis (AR) is a prevalent chronic inflammatory condition that significantly impacts patient quality of life and poses a substantial public health burden. Recent advancements in metabolomics have facilitated a deeper understanding of the metabolic pathways involved in AR, offering potential for new biomarkers and therapeutic targets.
Objective: This article aims to conduct a systematic review and meta-analysis of clinical studies summarizing the metabolomic profiles of allergic rhinitis (AR) to gain deeper insights into the metabolic changes and pathological processes underlying AR.
Coordinated regulation of eosinophil production and migration by glucocorticoids, prostaglandins, and cysteinyl-leukotrienes.
Int Immunopharmacol
January 2025
Laboratório de Citocinas Dept. of Immunology Instituto de Microbiologia Prof. Paulo de Góes Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil.
Introduction: The spectrum of eosinophil functions has expanded from fighting helminths to multiple novel roles in malignancy, infection, cancer, and metabolism. In asthma, glucocorticoids, prostaglandins (PG), and cysteinyl-leukotrienes (LT) regulate eosinophil biology through separate signaling pathways. Here we've evaluated the complex interplay between Dexa, PGE2, and CysLTs in eosinopoiesis and eosinophil biology in an allergic asthma model.
View Article and Find Full Text PDFSilibinin alleviates house dust mite induced allergic airway inflammation by inhibiting NLRC4 inflammasome and MMP-9 expression.
Biomed Pharmacother
January 2025
College of Veterinary Medicine and BK21 FOUR Program, Chonnam National University, 77 Yong-bong-ro, Buk-gu, Gwangju 61186, Republic of Korea. Electronic address:
Silibinin, a major compound of silymarin, has been reported to alleviate respiratory diseases including acute lung injury, asthma, chronic obstructive pulmonary disease, and pulmonary fibrosis through its antifibrotic, anti-inflammatory, and antioxidant properties. However, the specific mechanisms underlying its therapeutic effects, particularly in allergic asthma, are not fully understood. With the increasing prevalence and impact of allergic asthma, there is a need to elucidate the exact underlying mechanisms of its potential treatment effects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!